VMED02 - comment

No significant change in Q2 at VMED. Guidance has been firmed slightly in revenue but EBITDA is still expected to fall mid-single digits. We had expected marketing costs to continue to rise as the company offers discounts to protect customer numbers, and this is the case. The £850m of distributions to shareholders remains unchanged.